Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

224 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a multicenter, randomized, open-label Phase II trial that compares reduced dose erlotinib 100mg daily and standard dose gefitinib 250mg daily in patients with advanced non-small cell lung cancer who harbor EGFR mutations. The primary endpoint is disease control rate (DCR) and the key secondary endpoint is progression free survival (PFS). A total of 224 eligible patients will be randomized to receive either erlotinib 100mg daily or gefitinib 250mg daily in a 1:1 ratio until patients experience disease progression. Independent assessment of the major endpoints will be completed in a treatment-blinded manner. Randomization will be stratified based on treatment-lines (first-line vs. maintenance vs. second-line therapy). Tumor response and progression will be assessed according to RECIST 1.1.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

NCT01024413

Thoracic Neoplasms

COMPLETED PHASE3

Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation

NCT00874419

Non-small Cell Lung Cancer

COMPLETED PHASE3

High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

NCT01965275

Self Efficacy Drug Toxicity

UNKNOWN PHASE2

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

NCT01994057

Non-small Cell Lung Cancer (NSCLC) EGFR-TKI Resistant Mutation EGFR-TKI Sensitizing Mutation +2 more

RECRUITING

Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC

NCT02140333

NSCLC EGFR Mutation

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Stage Non Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Erlotinib100

Patients will be randomized to buy and receive erlotinib 100mg qd.

Group Type EXPERIMENTAL

Erlotinib 100mg qd

Intervention Type DRUG

Gefitinib250

Patients will be randomized to buy and receive gefitinib 250mg qd.

Group Type EXPERIMENTAL

Gefitinib 250mg qd

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Erlotinib 100mg qd

Intervention Type DRUG

Gefitinib 250mg qd

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosis of advanced stage NSCLC (stage IIIB or IV) which is confirmed by histology or cytology methods.
2. Harboring a PCR-confirmed activating mutation of EGFR, including an exon 19 deletion or an exon 21 L858R point mutation.
3. Measurable disease according to RECIST1.1.
4. Eastern Cooperative Oncology Group (ECOG) score of 0-2
5. Adequate organ function, defined as all of the following:

1. LVEF \>50% or within institution normal values.
2. Absolute neutrophil count (ANC)\>1500/mm3.
3. Platelet count \>75,000/mm3
4. Estimated creatinine clearance\>45m1/min.
5. Total bilirubin\<1.5 times institutional ULN (Patients with Gilbert's Syndrome total bilirubin must be \<4 times institutional ULN).
6. Aspartate amino transferase (AST) or alanine amino transferase (ALT) \< three times the institutional upper limit of normal (ULN) (if related to liver metastases\<five times institutional ULN).
6. Recovered from any previous therapy related toxicity to ≤CTCAE Grade 1 at study entry (except for stable sensory neurupethy ≤CTCAE Grade 2 and alopecia).
7. Ability to take oral medication in the opinion of the investigator.
8. Age ≥ 18 years.
9. Written informed consent that is consistent with ICH-GCP guidelines.

Exclusion Criteria

1. Prior treatment with EGFR directed small molecules or antibodies.
2. Radiotherapy within 4 weeks prior to randomization, except as follows:

1. Palliative radiation to target organs other than chest may be allowed up to 2 weeks prior to randomization
2. Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling.
3. Active brain metastases (stable for \<4 weeks, symptomatic, or leptomeningeal disease). Dexamethasone therapy will be allowed if administered as a stable dose for at least 4 weeks before randomization.
4. Any other current malignancy or malignancy diagnosed within the past three (3) years (other than basal-cell carcinoma of the skin, in situ cervical cancer, in situ prostate cancer).
5. Known pre-existing interstitial lung disease.
6. Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom e.g. Crohn's disease, malabsorption or CTC grade \>2 diarrhoea of any aetiology, based on investigator assessment.
7. History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3 (Refer to Appendix 10.4), unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior to randomisation.
8. Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the test drug.
9. Women of child-bearing potential and men who are able to father a child, unwilling to be abstinent or use adequate contraception prior to study entry, for the duration of study participation and for at least 2 months after treatment has ended. Adequate methods of contraception and women of Child-Beanng Potenial are discussed in Section 4.2.2.3.
10. Female patients of childbearing potential (see Section 4.2.2.3) who are nursing or are pregnant.
11. Patients unable to complv with the protocol in the opinion of the investigator.
12. Active hepatitis B infection (detined as presence of Hepatitis B DNA), active hepatitis C infection (defined as vresence of Hepatitis C RNA) and/or known HIV carrier.
13. Known or suspected active drug or alcohol abuse in the opinion of the investigator.
14. Requirement for treatment with any of the prohibited concomitant medications listed in Section 4.2.3.
15. Any contraindications for therapy with gefitinib or erlotinib.
16. Known hypersensitivity to erlotinib, gefitinib or the exipients of any of the trial drugs
17. Major surgery within 4 weeks of starting study treatment.
18. Use of any investigational drug within 4 weeks of randomisation (unless a longer time period is required by local regulations or by the guidelines for the investigational product).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No